Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT00846989

Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension

A 4-week Multi-center, Single-masked, Randomized, Latanoprost-controlled, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of RKI983 (0.05% and 0.10%) Ophthalmic Solution Given Twice a Day Versus Once Daily Latanoprost 0.005%, in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.

Sponsor: Novartis Pharmaceuticals

Conditions Glaucoma Ocular Hypertension

Interventions Latanoprost RKI983A

Updated 9 times since 2017 Last updated: Dec 11, 2020 Started: Jan 31, 2009 Primary completion: Apr 30, 2009 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00846989, this PHASE1/PHASE2 trial focuses on Glaucoma and Ocular Hypertension and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 9 times since 2009, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE1_PHASE2

▶ Show 4 earlier versions

Sep 2020 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Sep 2020 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Artesia, United States , Atlanta, United States , Bethpage, United States , Bossier City, United States , Cambridge, United States , Charlotte, United States , Danbury, United States , El Paso, United States , Houston, United States , Inglewood, United States and 18 more locations